Acorda Therapeutics Inc (ACOR)

14.25
NASDAQ : Health Care
Prev Close 14.55
Day Low/High 14.15 / 14.60
52 Wk Low/High 14.15 / 33.00
Avg Volume 1.12M
Exchange NASDAQ
Shares Outstanding 46.66M
Market Cap 678.89M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Acorda To Present At The Deutsche Bank 42nd Annual Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will present at the Deutsche Bank 42nd Annual Healthcare Conference in Boston on Thursday, May 4, 2017 at 11:20 a.

Biotech Movers: Intra-Cellular Therapies, Organovo, Acorda

Biotech Movers: Intra-Cellular Therapies, Organovo, Acorda

Intra-Cellular Therapies, Organovo Holdings and Acorda Therapeutics were among the biotech stock movers in premarket trading on Monday.

Acorda Expands Alexa Skill Offering For Parkinson's Awareness Month

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced the launch of The Many Faces of OFF¿ Facebook Feed, a new skill for the Amazon Alexa, as part of the company's activities in recognition of Parkinson's...

Acorda Shares Fall 5% in an Earnings Miss

Acorda Shares Fall 5% in an Earnings Miss

Net revenue for its Ampyra totaled $112 million, short of the $121 million consensus.

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

Acorda Provides Financial And Pipeline Update For First Quarter 2017

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced financial results for its first quarter ended March 31, 2017, and provided an update on the Company's pipeline, financial guidance and corporate restructuring.

Commit To Purchase Acorda Therapeutics At $13, Earn 14.2% Annualized Using Options

Investors considering a purchase of Acorda Therapeutics Inc shares, but tentative about paying the going market price of $16.35/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the October put at the $13 strike, which has a bid at the time of this writing of 90 cents.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AAN, CR, CVLT, CWCO, GPRK, KMB, MDLZ, MVC, OPB, POL, PW, RMBS, SNY Downgrades: ACOR, AKR, FCCY, NRZ, QGEN, SSY, SWFT, TBBK, WRI Initiations: UA Read on to get TheStreet Quant Ratings' detailed report:

Acorda To Host Conference Call To Discuss First Quarter 2017 On April 27, 2017

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its first quarter 2017 financial results and pipeline updates on Thursday, April 27 at 8:30 a.

Acorda CEO Risks All, Loses Nothing, When Drug Patent Strategy Backfires, Employees Fired

Acorda CEO Risks All, Loses Nothing, When Drug Patent Strategy Backfires, Employees Fired

Biotech is an inherently risky business, so layoffs are an unfortunate consequence of bad things happening. But Acorda's situation is a different because the company was extra risky from founding.

Acorda Therapeutics Implements Corporate Restructuring To Align Cost Structure With Focus On Promising Late-Stage Programs

Acorda Therapeutics, Inc. (Nasdaq:  ACOR) today announced a corporate restructuring to reduce its cost structure and focus its resources on its two late-stage programs, CVT-301 and tozadenant, as well as on maximizing...

Acorda Shares Fall 21% on Patent Ruling Loss That Clears Way for MS Generic

Acorda Shares Fall 21% on Patent Ruling Loss That Clears Way for MS Generic

A District Court judge found four Acorda patents on Ampyra were invalid due to obviousness.

U.S. District Court Issues Decision To Invalidate Four AMPYRA Patents; Company Will Appeal Ruling

Acorda Therapeutics, Inc. (Nasdaq:  ACOR ) today announced that the United States District Court for the District of Delaware upheld U.

Acorda Therapeutics Sinks on Invalidated Patents

Acorda Therapeutics Sinks on Invalidated Patents

Shares of the biopharmaceutical company were falling over 25% during midday trading.

Figure 1 (Graphic: Business Wire)

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced results from two ongoing, long-term safety studies of CVT-301 in people with Parkinson's that showed no differences in pulmonary function between the group receiving...

The MS Awareness Facts Skill Allows Users To Ask Amazon Alexa For An MS Awareness Fact To Learn More About Multiple Sclerosis And Find Helpful Information On MS And Its Symptoms.

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced the launch of its Alexa skill, MS Awareness Facts , as part of the company's activities in recognition of Multiple Sclerosis (MS) Awareness Month.

Patent Trials And Appeal Board (PTAB) Upholds Four AMPYRA® Patents

Acorda Therapeutics, Inc. (Nasdaq:  ACOR ) today announced that the United States Patent and Trademark Office (USPTO) Patent Trials and Appeal Board (PTAB) upheld all four patents challenged via the inter partes...

Acorda Stock Jumps Following Patent Challenge Win

Acorda Stock Jumps Following Patent Challenge Win

The challenge was brough by hedge fund manager Kyle Bass.

Acorda To Present At The Cowen And Company 37th Annual Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will present at the Cowen and Company 37th Annual Health Care Conference in Boston on Monday, March 6, 2017 at 1:20 p.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACOR, BAM, BCOR, CMFN, GG, INFO, LBTYA, LBTYK, MXC, WNRL Downgrades: AAN, BCOV, DE, GLAD, MCO, ROCK, RPAI, UEIC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Catherine D. Strader, Ph.D., Joins Acorda Therapeutics Board Of Directors

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Catherine D.

Analysts' Actions -- Acorda, Restoration Hardware, Humana, Merck and More

Analysts' Actions -- Acorda, Restoration Hardware, Humana, Merck and More

Here are Wednesday's top research calls, including upgrades for Acorda and Restoration Hardware, a price target increase for Humana and a price target cut for Merck.

Acorda Provides Financial And Pipeline Update For Fourth Quarter And Year End 2016

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a financial and pipeline update for the fourth quarter and full year ended December 31, 2016.

Acorda Therapeutics Stock Surges on Clinical Trial Results

Acorda Therapeutics Stock Surges on Clinical Trial Results

Acorda Therapeutics announced positive results in a clinical trial for its drug CVT-301.

Acorda, Amgen and Regeneron Lead Premarket Biotech Movers

Acorda, Amgen and Regeneron Lead Premarket Biotech Movers

Acorda was soaring ahead of the market open, thanks to positive late-stage clinical trial results for levodopa.

Acorda Therapeutics Inhaled Drug Reduces Parkinson's Motor Symptoms in Late-Stage Study

Acorda Therapeutics Inhaled Drug Reduces Parkinson's Motor Symptoms in Late-Stage Study

Acorda intends to file for U.S. marketing approval for the drug, CVT-301, in the second quarter, pending results from two long-term safety studies.